SSRI/SNRI Pregnancy Exposure Risks Should Be In Patient Labeling, Pediatric Subcmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Subcommittee rejects public health advisory on selective serotonin re-uptake inhibitor withdrawal syndrome risks to newborns. FDA is preparing class labeling that will add precautions to pregnancy section of SSRI/SNRIs.